iShares MSCI Taiwan ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Taiwan ETF trades at $100.25, while Cassava Sciences Inc trades at $1.1 (market cap $53.14M). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EWT | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $4.64 |
52-Week Low | $58.05 | $1.09 |
Market Cap | — | $53.14M |
Enterprise Value | — | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Taiwan ETF (EWT) trades at $100.08, down 1.77% on the day, consolidating after a significant rally that saw the fund more than double over the past year. Technical indicators show a neutral overall signal with mixed moving average and oscillator readings, while the fund remains strategically positioned at the center of the global AI infrastructure surge through its heavy exposure to Taiwan's semiconductor sector, led by TSMC.
The outlook for EWT is balanced between strong fundamental tailwinds from AI-driven semiconductor demand and significant geopolitical risks related to Taiwan-China tensions. While the fund offers concentrated exposure to a critical technology supply chain, stretched valuations and potential currency headwinds create near-term uncertainty for investors.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →